Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein

MLA

Al-Otaibi, Anirban Sengupta, et al. “Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein.” Vaccines; Volume 10; Issue 4; Pages: 504, Mar. 2022. EBSCOhost, https://doi.org/10.3390/vaccines10040504.

APA

Al-Otaibi, A. S., Mohammad Azharuddin, Maria E. Cardona, Claudia Devito, Eleanore von Castelmur, Anna Wehlin, Zuzanna Pietras, Maria Sunnerhagen, Robert Selegård, Daniel Aili, Ali Alamer, Jorma Hinkula, & Noha. (2022). Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein. Vaccines; Volume 10; Issue 4; Pages: 504. https://doi.org/10.3390/vaccines10040504

Chicago

Al-Otaibi, Anirban Sengupta, Mohammad Azharuddin, Maria E. Cardona, Claudia Devito, Eleanore von Castelmur, Anna Wehlin, Zuzanna Pietras, et al. 2022. “Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein.” Vaccines; Volume 10; Issue 4; Pages: 504, March. doi:10.3390/vaccines10040504.